Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 4Glioblastoma 3Astrocytoma 3Recurrence 2Central Nervous System Neoplasms 2Neoplasms 1Gliosarcoma 1Brain Neoplasms 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × IL13-PE38 × Clear all
NCT00024570 2014-11-14

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
60 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT00378235 2014-11-13

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Withdrawn
CNS

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡